Given the current limitations of EGFR and HER2-targeted drugs in treating breast cancer, new agents that act through a synthetic lethal mechanism could benefit patients with EGFR+ TNBCs and drug- resistant HER2+ tumors. The gene discussed is ERBB2; the disease is breast cancer.